top of page

Search Results

Results found for "Domain Therapeutics"

  • Dr. Juan JosĂ© Fung | Dr. GPCR Ecosystem

    Juan José Fung is a Principal Scientist at GPCR Therapeutics, Inc , a drug discovery company focused Juan José Fung on the web LinkedIn GPCR Therapeutics Dr. GPCR Ecosystem Unlock the Full Dr.

  • GPCR Pharmacology, Career Twists & Serendipity with Sokhom Pin | Dr. GPCR Ecosystem

    From his early work as a technician at Johns Hopkins Hospital to leading biology at Servo Therapeutics years of drug discovery research in the pharmaceutical industry, where he works mainly on GPCRs as therapeutic He is passionate about mechanistic profiling of therapeutic molecules as well as drug discovery in general

  • Dr. Khaled Abdelrahman | Dr. GPCR Ecosystem

    He received the Canadian Society of Pharmacology and Therapeutics Postdoctoral and Publication awards along with many Young Scientist Awards from the American Society for Pharmacology and Experimental Therapeutics

  • Terry HĂ©bert | Dr. GPCR Ecosystem

    Hebert's argument — that challenge trials depend on a reliable therapeutic the field did not yet have Challenge trials and the therapeutic floor — Why the ethics of accelerating vaccine trials depend on challenge trial — where volunteers receive placebo or active virus — is ethically unworkable without a therapeutic Terry Hébert is a Professor within the Department of Pharmacology & Therapeutics at McGill University

  • Paul Insel: Rethinking COVID-19 Pathobiology Through GPCR Signaling | Dr. GPCR Ecosystem

    The therapeutic logic that follows is less about attacking the virus and more about rebalancing a GPCR-driven Dry-lab pharmacology and what becomes possible when wet-lab work stops GPCR density and tissue-specific therapeutic The review was accepted at Clinical Pharmacology and Therapeutics within weeks. If the virus disrupts one arm of this receptor-peptide system, the therapeutic question stops being "

  • Dr. AurĂ©lien Rizk | Dr. GPCR Ecosystem

    the company's ability to predict the residence time of a ligand and its potential correlation with a therapeutic Therapeutic Effect and Receptor Interactions Aurelien Rizk and Yamina had a detailed discussion about the importance of gaining more information about the therapeutic effect in patients or animals and the They also shared their preference for small molecule therapies over protein therapeutics.

  • Dr. Katarina Nemec | Dr. GPCR Ecosystem

    I aim to discover new therapeutic approaches, and druggable molecules or refine canonical drug targets while performing various cell-based experiments to understand the binding, activation, and signaling of therapeutically

  • Dr. Rosie Dawaliby | Dr. GPCR Ecosystem

    In 2016, I joined a company that specialized in therapeutic candidate discovery targeting GPCR ( Confo Therapeutics ) as a team and project leader for antibody discovery for metabolic and inflammatory diseases

  • Dr. Stephane Angers | Dr. GPCR Ecosystem

    He is the scientific founder of two biotech companies, ModMab Therapeutics , and AntlerA Therapeutics

  • Bryan Roth: Inside the DARPA Bet on a Non-Psychedelic Psychedelic | Dr. GPCR Ecosystem

    The therapeutic mechanism, however, is inseparable from the psychedelic experience itself, and not every questions in current GPCR pharmacology: can biased signaling at the serotonin 2A receptor decouple the therapeutic What you usually can't do is know which pathway, in which disease, will actually be therapeutic. The premise: psilocybin's therapeutic effect on depression is now well documented, but it is locked to

  • Dr. Stuart Maudsley | Dr. GPCR Ecosystem

    At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based therapeutics

  • Dr. Stuart Maudsley | Dr. GPCR Ecosystem

    At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based therapeutics

  • Dr. Stuart Maudsley | Dr. GPCR Ecosystem

    At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based therapeutics

  • Celtarys Research | Dr. GPCR Ecosystem

    Biology: The Role of Fluorescent Ligands in GPCR Research GPCRs are one of the most important families of therapeutic Celtarys’ cutting-edge fluorescent ligand technology and accelerate the development of GPCR-targeted therapeutics accelerate the adoption of our chemical tools and foster collaborations that turn receptor biology into therapeutic

  • Signals, pH, and Discovery : Cracking GPCR Mysteries with Dr. Ian Chronis | Dr. GPCR Ecosystem

    Yamina underscores the therapeutic potential of GPR65, especially in the context of cancer immunotherapy , and how understanding receptor activity in acidic micro environments could unlock new therapeutic strategies

  • Elva Zhao: G Protein Regulation and Biased Signaling at the GLP-1 Receptor | Dr. GPCR Ecosystem

    the most clinically validated targets in metabolic disease - yet the signaling logic separating the therapeutic pharmacologists have not yet addressed actually shape signaling output at one of the field's most important therapeutic receptor Transducer coupling as the missing mechanistic layer in GLP-1 receptor pharmacology The expanding therapeutic modulate the functional output at this receptor, and whether that regulatory layer contributes to the therapeutic

  • Dr. Lauren M. Slosky | Dr. GPCR Ecosystem

    protein-coupled receptors (GPCRs) regulate motivated behavior and how these receptors can be targeted for therapeutic distinct signaling pathways with their physiological effects and may serve as the basis for more selective therapeutics

  • How Lipid Rafts Organize GPCR Signaling | Dr. GPCR Ecosystem

    Keyvan Sedaghat discussing how GPCR function is shaped by lipid raft compartmentalization, the expanding therapeutic efficacy and diagnostic innovation What the functional diversity of bitter taste receptors means for novel therapeutic

  • Fluorescent Probes for GLP-1R and GIPR Imaging: From Cell Assays to In Vivo Systems | Dr. GPCR Ecosystem

    His work carries direct translational relevance to diabetes and obesity therapeutics. opportunities for scientists and biotech leaders working across pharmacology, translational research, and therapeutic

  • Fiona Marshall: Three Decades Inside GPCR Drug Discovery | Dr. GPCR Ecosystem

    thermostabilization strategy finally made GPCR structures routine, the insight that seeded Heptares Therapeutics She co-founded Heptares Therapeutics and served as Chief Scientific Officer for twelve years, through As a co-founder of Heptares Therapeutics , now called Sosei Heptares , a GPCR-focused drug discovery

  • Receptor Signaling Bias: A Valuable and Accessible Property of New Drug Candidates | Dr. GPCR Ecosystem

    development, with 25+ years of expertise and validated cell-based assays spanning basic research through therapeutic opportunities for scientists and biotech leaders working across pharmacology, translational research, and therapeutic

  • Dr. Michael Feigin | Dr. GPCR Ecosystem

    Michael Feigin is an Associate Professor in the Department of Pharmacology and Therapeutics, and Director of Graduate Studies of Experimental Therapeutics at Roswell Park Comprehensive Cancer Center in Buffalo disrupting histone processing on rapidly proliferating cells, such as cancer cells, and suggested a therapeutic

  • Irfan Dhanidina, Dr. Kathleen Caron and Dr. Lauren Slosky | Dr. GPCR Ecosystem

    protein-coupled receptors (GPCRs) regulate motivated behavior and how these receptors can be targeted for therapeutic distinct signaling pathways with their physiological effects and may serve as the basis for more selective therapeutics

  • Yao Lu (Jackie) | Dr. GPCR Ecosystem

    molecular explanation of small molecules for their pre-clinical efficacy and to support the design of novel therapeutics

  • Exploring Career Paths in GPCR Research with Dr. Jacek MokrosiĹ„ski | Dr. GPCR Ecosystem

    Yamina will schedule a future talk with Jacek about GPCRs as therapeutic modalities. The discussion revealed their interest in GPCRs as therapeutic modalities and possible future collaborations

  • Tanishka S. Saraf | Dr. GPCR Ecosystem

    Saraf " My research focuses on evaluating and targeting serotonin 1A receptors for therapeutic outcomes

  • Dr. Jean-Philippe Pin | Dr. GPCR Ecosystem

    biosensors, cryo-EM, photoswitchable ligands, and nanobodies as pharmacological tools and potential therapeutic

  • spatiotemporal-organization-of-gpcr-signaling | Dr. GPCR Ecosystem

    how GPCRs signal from internal membranes such as endosomes and the Golgi, work with direct bearing on therapeutic

  • The Role of Quantitative Sciences in GPCRs with Dr. Nagarajan Vaidehi | Dr. GPCR Ecosystem

    She has advanced the use of computational methods to meet the challenges of designing therapeutics with

  • Dr. Andrew Tobin | Dr. GPCR Ecosystem

    vehicle by which Andrew is translating fundamental findings to commercial products is Keltic Pharma Therapeutics

bottom of page